Web Desc
Antibodies and Vaccines as Drugs for COVID-19 - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): David P. Humphreys, Pierre Bruhns, Patrick C. Wilson and Esther Breij
Date: January 13 - 14, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Sponsored by 10x Genomics, BioLegend, Inc., Genentech, Inc., Genmab A/S and Merck & Co., Inc.
For important information on the coronavirus, please click here
Summary of Meeting:
COVID-19 has brought unprecedented society level attention on a truly global scale into antibody and vaccine science and technology. Billions of people are now aware of antibodies, therapeutic, protective and diagnostic and vaccine design, manufacturing and clinical trial design. On a medical level, COVID-19 has impacted every single country on the planet with currently 68 million confirmed infections and 1.5 million deaths. These numbers will continue to increase until natural immunity, improved therapeutic interventions, vaccines or a combination of all three succeed. Vaccines are a reality – clinical administration has started. Interventional antibodies are in late stage trials. This COVID event is simply the biggest medical and economic threat in modern history and antibody and vaccine science is at its core. This conference will bring together in an accessible on-line format key influencers and scientific advances from around the world and unite the scientific community in the first steps of defeating COVID-19. Keystone is unable to host its “Antibodies as Drugs” meeting as planned in January 2021 but will be replaced in part in a smaller COVID focused on-line meeting called “Antibodies and Vaccines as Drugs for COVID-19”. The meeting will have two 2½ hour on-line sessions, timed to fit in with most major time zones, each comprised of nine x 10 minutes invited oral presentations. One session will have a dedicated therapeutic antibody focus the other will have a vaccine focus. An on-line poster session is planned. Join the meeting to find out the very latest about COVID-19 therapeutic developments.
Scholarship Deadline: November 1 2020
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
10x GenomicsBioLegend, Inc.Genentech, Inc.Genmab A/SMerck & Co., Inc.
We gratefully acknowledge additional support for this conference from:
DCVC Bio
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 1 of 12
* David P. Humphreys, UCB Pharma, UK

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 2 of 12
* Esther Breij, Genmab, Netherlands

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 3 of 12
Bo Barnhart, Abcellera Biologics Inc., Canada
Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 4 of 12
Christos Kyratsous, Regeneron Pharmaceuticals Inc, USA
Rapid Selection, Characterization and Clinical Development of Fully-Human Antibodies Against Emerging Infectious Diseases

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 5 of 12
Davide Corti, Humabs BioMed SA, Switzerland
Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)



Coffee Break

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 7 of 12
X. Sunney Xie, Peking University, China
COVID-19 Neutralizing Antibodies Screened by Single Cell Genomics

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 8 of 12
Linqi Zhang, Tsinghua University, China
Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 9 of 12
Xavier Saelens, Ghent University, Belgium
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID-19

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 10 of 12
Michael Stumpp, Molecular Partners, Switzerland
Highly Potent Anti-SARS-CoV-2 Multivalent DARP in Therapeutic Candidates

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 11 of 12
Michael G. Ison, Northwestern/Celltrion, Inc., USA
Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS-CoV-2 Infection

Wednesday, January 13 | 7:00AM - 9:30AM
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time S
tart)


Speaker 12 of 12
Natalia Freund, Tel Aviv University, Israel
Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Wednesday, January 13 | 11:00AM - 1:00PM
Poster Session (11am Denver/Mountain Time Start)


Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 1 of 12
* David P. Humphreys, UCB Pharma, UK

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 2 of 12
* Pierre Bruhns, Institut Pasteur, France

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 3 of 12
Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center, USA
The Challenges of a New Vaccine for a New Disease

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 4 of 12
Paul F. McKay, Imperial College, UK
Development of a Self-Amplifying RNA Vaccine for COVID-19

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 5 of 12
Andrea Carfi, Moderna, USA
Potent Vaccine Efficacy from mRNA-1273 Expressing SARS-CoV-2 Spike Protein Stabilized in the Prefusion Conformation

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 6 of 12
Alexander Muik, BioNTech, Germany
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 7 of 12
Trevor RF Smith, Inovio, USA
Development of INO-4800, a DNA Vaccine for COVID-19

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 8 of 12
Sarah Catherine Gilbert, University of Oxford, UK
Development of ChAdOx1 nCoV-19 (AZD1222); Creating a Vaccine in a Pandemic Setting

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)



Coffee Break

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 10 of 12
Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Janssen’s Efforts in the Development of an Ad26 Based COVID-19 Vaccine

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 11 of 12
Susanne Rauch, CureVac GmbH, Germany
Development of the mRNA based SARS-CoV-2 Vaccine CVnCoV

Thursday, January 14 | 7:00AM - 9:20AM
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Sta
rt)


Speaker 12 of 12
Neeltje van Doremalen, NIAID, National Institutes of Health, USA
Intranasal Vaccination with ChAdOx1 nCoV-19 Results in Reduced Nasal Shedding and Lack of Lower Respiratory Tract Infection in SARS-CoV-2 Hamsters and Rhesus macaques

Thursday, January 14 | 9:20AM - 9:30AM
Closing Remarks (9:20am Denver/Mountain Time Start)


Thursday, January 14 | 10:00AM - 12:00PM
Networking Lounge (10am Denver/Mountain Time Start)


*Session Chair.